CompletedPhase 2

A Study to Evaluate Safety and Tolerability of QLS-101 in NTG

United States30 participantsStarted 2021-09-15

Plain-language summary

A randomized active-controlled multi-site double-masked 28 day study to evaluate the safety and tolerability of QLS-101 versus timolol maleate Preservative Free (PF) 0.5% ophthalmic solution in subjects with normal tension glaucoma

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Visual acuity +1.0 logMAR or better
✓. Willing to give informed consent
✓. Ability to washout from current intraocular pressure lowering medications -

Exclusion criteria

✕. All secondary glaucomas
✕. Previous glaucoma intraocular or laser surgery (selective laser trabeculoplasty permitted when done 18 months or longer from Screening)
✕. Refractive surgery
✕. Ocular infection or inflammation

What they're measuring

Ocular safety

Timeframe: 86 days

Trial details

NCT IDNCT04857827

SponsorQlaris Bio, Inc.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2022-08-26

View on ClinicalTrials.gov More Normal Tension Glaucoma (NTG) trials